NCT01748929 is a Phase 4 clinical trial of Albendazole in Intestinal Diseases, Parasitic, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre.

What drugs are being tested in NCT01748929?

Interventions in NCT01748929: Albendazole, Placebo.

What condition does NCT01748929 study?

NCT01748929 studies Intestinal Diseases, Parasitic.

Is NCT01748929 still recruiting?

NCT01748929 is currently completed. Last updated 29 August 2017.

Last reviewed 2017-08-29 · How we verify

NCT01748929

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth

Completed Phase 4 Last updated 29 August 2017

What this trial tests

Phase 4 trial testing Albendazole in Intestinal Diseases, Parasitic in 1,010 participants. Completed in 16 September 2016.

Timeline

24 February 2014

Primary endpoint
13 February 2015

16 September 2016

Quick facts

Lead sponsor	McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	1,010
Start date	24 February 2014
Primary completion	13 February 2015
Estimated completion	16 September 2016
Sites	1 location across Peru

Drugs / interventions tested

Albendazole (ALBENDAZOLE) — full drug profile →
Placebo

Conditions studied

Intestinal Diseases, Parasitic — all drugs for Intestinal Diseases, Parasitic →

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Who can join

Eligibility, female only, with Intestinal Diseases, Parasitic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Women of reproductive age are considered a high-risk group for worm infections by the World Health Organization. Maternal infection and anemia contribute to infant malnutrition by affecting milk quality and quantity, and duration of exclusive breastfeeding. To date, no study has investigated the health benefits of postpartum deworming to infants or mothers. A randomized controlled trial will be conducted in Peru to investigate the effectiveness of integrating deworming into routine postpartum care. The primary measure of effect will be infant weight gain between birth and six months of age. Other infant and maternal health indicators will also be ascertained.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

A Double-Blind Randomized Controlled Trial of Maternal Postpartum Deworming to Improve Infant Weight Gain in the Peruvian Amazon.
Mofid LS, Casapía M, Aguilar E, Silva H, et al · · 2017 · cited 13× · PMID 28056024 · DOI 10.1371/journal.pntd.0005098
Interventions to improve linear growth during exclusive breastfeeding life-stage for children aged 0-6 months living in low- and middle-income countries: a systematic review with network and pairwise meta-analyses.
Park JJH, Siden E, Harari O, Dron L, et al · · 2019 · cited 11× · PMID 33062941 · DOI 10.12688/gatesopenres.13082.2
Maternal Deworming Research Study (MADRES) protocol: a double-blind, placebo-controlled randomised trial to determine the effectiveness of deworming in the immediate postpartum period.
Mofid LS, Casapía M, Montresor A, Rahme E, et al · · 2015 · cited 7× · PMID 26084556 · DOI 10.1136/bmjopen-2015-008560
Maternal postpartum deworming and infant milk intake: Secondary outcomes from a trial.
Mofid LS, Casapía M, Montresor A, Rahme E, et al · · 2021 · cited 5× · PMID 33729674 · DOI 10.1111/mcn.13183

Verify or expand the search:

Other trials of Albendazole

Trials testing the same drug.

NCT07074444 — Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel · Phase 4 · recruiting
NCT04713787 — A Safety and Efficacy Study of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole to Treat Trichuri · Phase 2 · recruiting
NCT06265870 — Specific Versus Empirical Anthelminthic Treatment in Eosinophilia · NA · recruiting
NCT06483880 — The Role of Adjuvant Albendazole After Pulmonary Hydatid Cyst Resection · NA · unknown
NCT05453045 — Pharmacokinetics and Excretion of Albendazole and Its Metabolites in Saliva · NA · unknown

Other McGill University Health Centre/Research Institute of the McGill University Health Centre trials

Trials by the same sponsor.

NCT07439406 — Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy · Phase 2 · not yet recruiting
NCT07328971 — Vancomycin Taper to Prevent Recurrent Clostridioides Difficile · Phase 3 · not yet recruiting
NCT07556952 — Dex & Mastectomy Pain · Phase 4 · recruiting
NCT07069582 — Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women · Phase 1 · not yet recruiting
NCT07386171 — Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01748929 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by McGill University Health Centre/Research Institute of the McGill University Health Centre
Last refreshed: 29 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01748929.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing